Related Experiment Videos
A comparative study of intravenous accelerated streptokinase dose regimen with conventional dose regimen for coronary
Insights
Accelerated streptokinase therapy for acute myocardial infarction shows improved coronary artery reperfusion rates compared to conventional dosing. This faster regimen appears safe, with similar adverse event profiles, warranting further investigation.
Area of Science:
- Cardiology
- Pharmacology
- Emergency Medicine
Background:
- Acute myocardial infarction (AMI) requires prompt restoration of coronary blood flow.
- Thrombolytic therapy, including streptokinase, is a key treatment for AMI.
- Optimizing thrombolytic regimens is crucial for improving patient outcomes.
Purpose of the Study:
- To compare the efficacy and safety of an accelerated streptokinase dose regimen versus a conventional regimen for coronary thrombolysis in AMI patients.
- To evaluate the patency rate and reperfusion success of the two streptokinase dosing strategies.
Main Methods:
- A randomized trial involving 104 patients with definite AMI within 12 hours of symptom onset.
- Patients received either accelerated (1.5 million units/30 min) or conventional (1.5 million units/60 min) intravenous streptokinase.
- Reperfusion was assessed by clinical evidence, with subgroup analysis for patients presenting within 6 hours.
Main Results:
- The accelerated regimen achieved a higher reperfusion rate (76.6%) compared to the conventional regimen (61.4%).
- This difference was statistically significant in patients treated within 6 hours of chest pain onset (87.9% vs. 67.4%, P < 0.05).
- Incidence of mild bleeding, allergic reactions, and hypotension was comparable between the groups.
Conclusions:
- The accelerated streptokinase dose regimen demonstrates improved reperfusion rates in AMI without a significant increase in adverse events.
- This faster thrombolytic approach holds promise for more effective treatment of acute myocardial infarction.
- Further extensive investigation into accelerated streptokinase therapy is recommended.
Abstract:
The aim of this study is to test the patency rate and safety of the accelerated streptokinase dose regimen for coronary thrombolysis compared with the conventional one. One hundred and four patients entering three hospitals up to 12 hours after the onset of definite acute myocardial infarction were randomizely treated with intravenous accelerated streptokinase dose regimen (1.5 million units/30 min) (group A, 47 cases) and conventional dose regimen (1.5 million units/60 min) (group B, 57 casese). The reperfusion rate of infarct-related arteries determined by clinical evidence of reperfusion was 76.6% (36/47) in group A VS 61.4% (35/57) in group B. There was significant difference in reperfusion rates among patients within 6 hours after the onset of chest pain: 87.9% (29/33) in group A VS 67.4 (29/43) in group B (P < 0.05). The incidence of mild bleeding, allergic reaction, hypotension was 12.8% (6/47), 4.3% (2/47), 12.8 (6/47) respectively in group A vs 21.1 (12/57), 3.5 (2/57), 17.5% (10/57) respectively in group B. Compared to conventional dose regimen, intravenous accelerated streptokinase dose regimen for coronary thrombolysis seems to improve reperfusion rate markedly without increasing adverse events such as bleeding, allergic reaction and hypotension. It suggests that accelerated streptokinase therapy deserves more extensive investigation.